Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

58 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
4-anilino-5-carboxamido-2-pyridone derivatives as noncompetitive inhibitors of mitogen-activated protein kinase kinase.
Spicer JA, Rewcastle GW, Kaufman MD, Black SL, Plummer MS, Denny WA, Quin J 3rd, Shahripour AB, Barrett SD, Whitehead CE, Milbank JB, Ohren JF, Gowan RC, Omer C, Camp HS, Esmaeil N, Moore K, Sebolt-Leopold JS, Pryzbranowski S, Merriman RL, Ortwine DF, Warmus JS, Flamme CM, Pavlovsky AG, Tecle H. Spicer JA, et al. J Med Chem. 2007 Oct 18;50(21):5090-102. doi: 10.1021/jm0704548. Epub 2007 Sep 19. J Med Chem. 2007. PMID: 17880056
Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition.
Ohren JF, Chen H, Pavlovsky A, Whitehead C, Zhang E, Kuffa P, Yan C, McConnell P, Spessard C, Banotai C, Mueller WT, Delaney A, Omer C, Sebolt-Leopold J, Dudley DT, Leung IK, Flamme C, Warmus J, Kaufman M, Barrett S, Tecle H, Hasemann CA. Ohren JF, et al. Nat Struct Mol Biol. 2004 Dec;11(12):1192-7. doi: 10.1038/nsmb859. Epub 2004 Nov 14. Nat Struct Mol Biol. 2004. PMID: 15543157
Inhibitors of Bcr-abl... breaking new ground again.
Ohren JF, Sebolt-Leopold JS. Ohren JF, et al. Nat Chem Biol. 2006 Feb;2(2):63-4. doi: 10.1038/nchembio0206-63. Nat Chem Biol. 2006. PMID: 16421581 No abstract available.
The discovery of the benzhydroxamate MEK inhibitors CI-1040 and PD 0325901.
Barrett SD, Bridges AJ, Dudley DT, Saltiel AR, Fergus JH, Flamme CM, Delaney AM, Kaufman M, LePage S, Leopold WR, Przybranowski SA, Sebolt-Leopold J, Van Becelaere K, Doherty AM, Kennedy RM, Marston D, Howard WA Jr, Smith Y, Warmus JS, Tecle H. Barrett SD, et al. Bioorg Med Chem Lett. 2008 Dec 15;18(24):6501-4. doi: 10.1016/j.bmcl.2008.10.054. Epub 2008 Oct 15. Bioorg Med Chem Lett. 2008. PMID: 18952427
Oncogenic Mutants of MEK1: A Trilogy Unfolds.
Maust JD, Whitehead CE, Sebolt-Leopold JS. Maust JD, et al. Among authors: sebolt leopold js. Cancer Discov. 2018 May;8(5):534-536. doi: 10.1158/2159-8290.CD-18-0192. Cancer Discov. 2018. PMID: 29716939
Deciphering the Complexity of MEK Mutations in the Clinic.
Whitehead CE, Sebolt-Leopold JS. Whitehead CE, et al. Among authors: sebolt leopold js. Cancer Res. 2020 Oct 1;80(19):4042-4043. doi: 10.1158/0008-5472.CAN-20-2611. Cancer Res. 2020. PMID: 33008803
58 results